ORIGINAL ARTICLE

Statins and the risk of pancreatic cancer: A systematic review and meta-analysis of 2,797,186 patients

Eryka Karbowska[1], Damian Swieczkowski[2], Aleksandra Gasecka[3], Michal Pruc[4],
Kamil Safiejko[5], Jerzy R. Ladny[6], Tomasz Kopiec[3], Milosz J. Jaguszewski[7],
Krzysztof J. Filipiak[8], Zubaid Rafique[9], Lukasz Szarpak[9–11]

[1]Department of CT and MR Radiology, Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland
[2]Department of Toxicology, Faculty of Pharmacy, Medical University of Gdansk, Poland
[3]1st Chair and Department of Cardiology, Medical University of Warsaw, Poland
[4]Research Unit, Polish Society of Disaster Medicine, Warsaw, Poland
[5]Colorectal Cancer Unit, Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland
[6]Department of Emergency Medicine, Medical University of Bialystok, Poland
[7]1st Department of Cardiology, Medical University of Gdansk, Poland
[8]Institute of Clinical Science, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland
[9]Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, United States
[10]Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland
[11]Research Unit, Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland

This paper was guest edited by Prof. Togay Evrin

Abstract

Background: *Statin use in many studies is related to the improvement of a patients' condition including reducing the risk of various malignancies. Herein, is a systematic review and meta-analysis to examine the evidence on the association between statin therapy and the risk of the occurrence of pancreatic cancer, mainly in terms of decreased risk of developing pancreatic cancer among patients using statin therapy in the long-term perspective.*

Methods: *PubMed, Web of Science, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from database inception to December 1st, 2021. Random effect models were used to estimate summary odds ratios (OR) and the corresponding 95% confidence intervals (CI).*

Results: *A total of 26 studies comprising 2,797,186 patients were included. Polled analysis showed that pancreatic cancer occurrence in statin vs. no-statin group varied and amounted to 0.4% vs. 0.6% (OR = 0.83; 95% CI: 0.72–0.96; I^2 = 84%; p = 0.01).*

Conclusions: *In summary, the present analysis shows that overall statins use is significantly associated with a reduction in risk of pancreatic cancer. However, these results were not confirmed for the randomized controlled trial subgroup. Further prospective studies are needed to confirm the current results.* (Cardiol J 2024; 31, 2: 243–250)

Keywords: pancreatic cancer, pancreatic malignancy, statin, risk, systematic review, meta-analysis

Address for correspondence: Lukasz Szarpak, Assoc. Prof., PhD, DPH, DBA, LL.M., Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, United States, e-mail: lukasz.szarpak@bcm.edu

Introduction

Due to the fact that pancreatic cancer is usually diagnosed in advanced stages, i.e., the presence of distant metastases is identified in more than 50% of patients at the time of diagnosis, this malignant neoplasm remains one with the worst prognosis [1]. Even considering the introduction of modern chemotherapeutic regimens (FOLFIRINOX, nab-paclitaxel with gemcitabine) and the development of pancreatic surgery — the 5-year survival rate remains low, especially compared to other solid tumors [2, 3]. Screening tests are only recommended in patients at very high risk of developing pancreatic cancer, for example, in certain genetic syndromes. Moreover, there is also no clear consensus on the type of screening (computed tomography, magnetic resonance imaging, endoscopic ultrasound) as well as the frequency of recommended testing [4]. The search for ways to reduce the risk of developing pancreatic cancer has led to providing rather general health-related recommendations, including a balanced diet, maintaining a healthy body weight, physical activity, or quitting smoking [5].

In addition, the search for relationships between pharmacotherapy (particularly long-term) and the risk of pancreatic cancer, particularly in the context of a reduced risk of developing this malignancy is highly warranted. Scientists have long highlighted the relationship between the use of acetylsalicylic acid (ASA) and a reduction in the risk of solid tumors, including pancreatic cancer — although the relationship is not as clear as it is in the case of, for example, colorectal cancer [6]. ASA has a pleiotropic effect, and the key to observing its impact on reducing the risk of pancreatic cancer is the length of its use [7]. Studies are also examining a connection between nonsteroidal anti-inflammatory drug (NSAIDs) use and the risk of pancreatic cancer [8]. Due to the fact that NSAIDs constitute a heterogeneous group of drugs and patients use anti-inflammatory drugs both chronically and sporadically — depending on the need and pain level — it is challenging to find any well-established relationship [9, 10].

On the other hand, due to the population potential and the fact that statins are used in long-term therapy, it is not surprising that scientists are interested in looking for evidence on the impact of their use on cancer risk [11]. Basic science research seems to indicate that there is a pancreatic carcinogenesis mechanism that can be influenced by statins [12]. From a clinical point of view, thanks to statins, one can obtain better control over the risk factors of pancreatic cancer, including the metabolic profile and obesity. Moreover, in patients diagnosed with pancreatic cancer, especially metastatic, statins appear to improve overall survival [13]. It may be related to the chemosensitizing properties of statins. Bearing in mind the evidence from basic science, preclinical studies in animal models as well as clinical observations, it is reasonable to conduct epidemiological observations aimed at demonstrating the relationship between long-term statin use and the risk of pancreatic cancer [14]. Conflicting results of observational studies, high heterogeneity of populations covered by epidemiological observations, and finally, different methodologies applied in studies make it difficult to analyze the available data objectively.

The above-mentioned factors, have mainly contradictory results in epidemiological observations and have led to the necessity of conducting a systematic review of the literature and a meta-analysis — which findings may be valuable in designing other prospective scientific studies. Thus, the present study conducted a systematic review and meta-analysis to examine the evidence on the association between statin therapy and the risk of occurrence of pancreatic cancer, mainly in terms of decreased risk of developing pancreatic cancer among patients using statin therapy in the long-term perspective.

Methods

The current study was designed as a systematic review and meta-analysis. It was performed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) statement [15]. The study protocol has been deposited in the PROSPERO database prior to the start of the study. No protocol changes were made during the study. Due to the nature of the study (meta-analysis), the bioethical commission approval was not required.

Literature search

A computerized literature search of PubMed, Web of Science, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) was performed from each databases' inception to December 1st, 2021. To increase the probability of identifying all relevant articles, a specific research equation was formulated for each database, using the following keywords: "pancreatic malignancy" OR "pancreatic cancer" OR "pancreatic neoplasm"

AND "statin" OR "autorvastatin" OR "fluvasta-tin" OR "cerivastatin" OR "lovastatin" OR "re-suvastatin" OR "pravastatin" OR "simvastatin". Additionally, the reference list of the eligible trial and relevant review articles were crosschecked to identify additional pertinent studies.

Inclusion and exclusion criteria

Studies that were included in this meta-analysis had to fulfill the following PICOS criteria: 1) Participants, patients were 18 years old or older; 2) Intervention, treatment with statin; 3) Comparison, treatment without statin; 4) Outcomes, pancreatic cancer occurrence; 5) Study design: retrospective and prospective trials published in English. Studies were excluded if they were reviews, animal studies, case reports, letters, conference or poster abstracts, or articles not containing original data.

Data extraction

Two reviewers (K.S. and L.S.) independently extracted the following information from each included article. From studies that met the inclusion eligibility criteria, the following data were extracted into predefined Microsoft Excel spreadsheet (Microsoft Corp., Redmond, WA, USA): a) Study characteristic (i.e.: first author, year of publication, country, study design); b) Participant characteristics (i.e.: number of participants, age, sex); c) Main study outcomes (i.e.: incidence of pancreatic cancer in each study group). Potential disagreements were resolved by discussion with third reviewer (K.J.F.).

Risk of bias

Two reviewers (K.S. and L.S.) independently assessed the risk of bias using the Cochrane "Risk of Bias" tool. The RoB-2 tool was used to assess the risk of bias among randomized controlled trials (RCT) [16], and ROBINS-I tool for non-randomized trials [17], respectively. Any disagreements between the two reviewers in the evaluation process were resolved by discussion with third reviewer (M.J.J.). The risk of bias assessments was visualized using the Robvis application [18].

Statistical analysis

The meta-analysis was conducted using the Review Manager, version 5.4EN (RevMan; The Cochrane Collaboration, Oxford, UK). A p value less than 0.05 was accepted as statistically significant. For each study, event numbers in relation to the pancreatic cancer occurrence were collected. The pooled results are presented as odds ratios

(OR) and 95% confidence intervals (CI). Random-effects models were used as they considered both sampling variance within the different trials and the variation in the underlying effect across studies. The quality of the heterogeneity was assessed by means of the Cochran's Q and I^2 statistics. Heterogeneity was determined with the I^2 statistic, in which the results range from 0% to 100%. Heterogeneity was interpreted as not observed when $I^2 = 0\%$, low when $I^2 = 25\%$, medium when $I^2 = 50\%$, and high when $I^2 = 75\%$ [19].

Results

Search results and characteristics of studies

As illustrated in Figure 1, 712 studies were identified in the literature search, and 47 were selected for full-text review. A total of 26 studies [20–45] met the inclusion criteria and were included in the analysis, comprising 2,797,186 patients. A manual search did not identify any new eligible studies. Baseline data and other details are shown in **Supplementary Table S1**. Two studies were randomized controlled trials [26, 40] and other trials were non-RCTs [20–25, 27–39, 41–45]. The results of the assessment of risk of bias among the 4 included studies are provided in **Supplementary Figures S1–S4**.

Meta-analysis

Twenty-six studies reported impact of statin use on pancreatic cancer occurrence. Polled analysis of those trials showed that pancreatic cancer occurrence in statin vs. no-statin group varied and amounted to 0.4% vs. 0.6% (OR = 0.83; 95% CI: 0.72–0.96; $I^2 = 84\%$; p = 0.01; Fig. 2). Sub-analysis showed that pancreatic cancer occurrence in statin vs. no-statin group in RCT was at the same level 0.3% (OR = 0.99; 95% CI: 0.44–2.23; $I^2 = 0\%$; p = 0.99), but in the non-RCT pancreatic cancer occurrence was 0.4% in the statin group, and 0.6% in the non-statin group (OR = 0.83; 95% CI: 0.72–0.96; $I^2 = 86\%$; p = 0.01).

When matched data were included in pooled analysis occurrence on pancreatic cancer 0.4% in the statin group compared to 0.5% for the non-statin group (OR = 0.85; 95% CI: 0.71–0.95; $I^2 = 85\%$; p = 0.01).

The analysis of the effect of the duration of taking statins showed no statistically significant differences with the incidence of cancer in the group of patients who took statins < 48 months and ≥ 48 months, respectively (5.7% vs. 5.1%; OR = 1.20; 95% CI: 0.98–1.45; $I^2 = 64\%$; p = 0.07; Fig. 3).

Figure 1. Flow diagram showing stages of database searching and study selection as per Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) guideline.

Discussion

This meta-analysis indicates the protective role of statins in the prevention of pancreatic cancer. Although due to the high heterogeneity of the studies included in the meta-analysis and the observational nature of the studies — especially in the case of case-control studies (retrospective analysis), strong recommendations regarding the use of statins in the prevention of pancreatic cancer are impossible to provide. Similar conclusions as in the present meta-analysis can be found in the meta-analysis published in 2019, which included 26 studies [46]. Archibugi et al. [47] also showed that long-term use of statins (especially atorvastatin) might be associated with a significant reduction in the risk of developing pancreatic cancer (OR 0.70; 95% CI: 0.60–0.82; $p < 0.001$). Previous observations, however, indicated that the protective effect of statins on the development of pancreatic cancer is more questionable, especially at doses routinely used in the treatment of lipid disorders. The use of higher doses has not been routinely recommended due to the patients' worries of side effects [48]. However, it is changing nowadays with the new guidelines and new treatment goals. Finally, our meta-analysis should be understood to be taking into consideration the difference between the pancreatic cancer occurrence between two sub-categories: i) RCTs and; ii) Observational studies. Results obtained from observational studies are at a higher risk of bias compared to data obtained from RCTs. A sub-analysis was conducted to minimize bias in our meta-analysis. In addition, the previous meta-analyzes were created over 2 years ago, therefore, considering the significant development of medical sciences, it seems necessary to conduct a new analysis [45, 47]. Moreover, the high heterogeneity of the studies included in the analysis and the slight difference in effect additionally strengthen the need for another meta-analysis. In the correspondence accompanying this paper, it was suggested that it would be important to conduct research aimed at investigating the association between statins and other drugs used simultaneously on the prognosis in pancreatic cancer. One should also pay attention to the dose-response relationship — a research hypothesis could be made that higher doses of statins should show a greater protective effect [49, 46].

Study or Subgroup	Statin Events	Total	No-Statin Events	Total	Weight	Odds Ratio M-H, Random, 95% CI	Odds Ratio M-H, Random, 95% CI
2.7.1 RCT							
Clearfield 2001	1	499	1	498	0.3%	1.00 [0.06, 16.00]	
Serruys 2002	2	844	1	833	0.3%	1.98 [0.18, 21.84]	
Strandberg 2004	9	2221	10	2223	1.8%	0.90 [0.37, 2.22]	
Subtotal (95% CI)		**3564**		**3554**	**2.4%**	**0.99 [0.44, 2.23]**	
Total events	12		12				
Heterogeneity: Tau^2 = 0.00; Chi^2 = 0.36, df = 2 (P = 0.83); I^2 = 0%							
Test for overall effect: Z = 0.02 (P = 0.99)							
2.7.2 Non-RCT							
Archibugi 2017	74	277	334	947	5.0%	0.67 [0.50, 0.90]	
Bang 2018	31	1696	86	3111	4.1%	0.65 [0.43, 0.99]	
Bradley 2010	148	1118	993	7977	5.8%	1.07 [0.89, 1.29]	
Carey 2013	59	164	193	592	4.5%	1.16 [0.81, 1.67]	
Chen 2015	611	450282	1730	690335	6.2%	0.54 [0.49, 0.59]	
Chiu 2011	39	186	151	574	4.2%	0.74 [0.50, 1.11]	
Coogan 2007	10	190	208	3652	2.7%	0.92 [0.48, 1.77]	
Graaf 2004	193	1444	2936	18661	5.9%	0.83 [0.71, 0.97]	
Haukka 2009	936	25445	962	24849	6.2%	0.95 [0.87, 1.04]	
Jacobs 2011	27	48261	300	712300	4.3%	1.33 [0.90, 1.97]	
Kabat 2017	13	1257	143	15265	3.1%	1.11 [0.62, 1.96]	
Karp 2008	9	11338	29	18738	2.3%	0.51 [0.24, 1.08]	
Kaye 2004	12	3244	53	14844	2.8%	1.04 [0.55, 1.94]	
Kho 2016	187	424	323	733	5.4%	1.00 [0.79, 1.27]	
Khurana 2007	122	163467	353	320266	5.6%	0.68 [0.55, 0.83]	
Kirkegård 2020	21	2318	132	5993	3.8%	0.41 [0.26, 0.64]	
Leung 2012	26	6841	205	27364	4.2%	0.51 [0.34, 0.76]	
Marelli 2011	29	5215	40	5094	3.7%	0.71 [0.44, 1.14]	
Peto 2008	8	11263	8	11227	1.6%	1.00 [0.37, 2.66]	
Sato 2006	1	179	1	84	0.2%	0.47 [0.03, 7.55]	
Simon 2016	29	12127	352	148451	4.4%	1.01 [0.69, 1.47]	
Vinogradova 2011	365	2110	1397	8762	6.1%	1.10 [0.97, 1.25]	
Walker 2015	175	501	310	902	5.5%	1.03 [0.82, 1.29]	
Subtotal (95% CI)		**749347**		**2040721**	**97.6%**	**0.83 [0.72, 0.96]**	
Total events	3125		11239				
Heterogeneity: Tau^2 = 0.08; Chi^2 = 158.69, df = 22 (P < 0.00001); I^2 = 86%							
Test for overall effect: Z = 2.57 (P = 0.01)							
Total (95% CI)		**752911**		**2044275**	**100.0%**	**0.83 [0.72, 0.96]**	
Total events	3137		11251				
Heterogeneity: Tau^2 = 0.08; Chi^2 = 159.29, df = 25 (P < 0.00001); I^2 = 84%							
Test for overall effect: Z = 2.56 (P = 0.01)							
Test for subgroup differences: Chi^2 = 0.19, df = 1 (P = 0.66), I^2 = 0%							

0.05 0.2 1 5 20
Statin No-Statin

Figure 2. Forest plot of pancreatic cancer occurrence rate among statin vs. non-statin groups. The center of each square represents the weighted risk ratios for individual trials, and the corresponding horizontal line stands for a 95% confidence interval (CI). The diamonds represent pooled results.

Study or Subgroup	< 48 months Events	Total	≥ 48 months Events	Total	Weight	Odds Ratio M-H, Random, 95% CI	Odds Ratio M-H, Random, 95% CI
Bradley 2010	120	752	29	214	12.8%	1.21 [0.78, 1.88]	
Graaf 2004	3007	16435	33	276	15.8%	1.65 [1.14, 2.38]	
Haukka 2009	5319	16036	3089	9409	35.0%	1.02 [0.96, 1.07]	
Khurana 2007	95	112622	27	50723	13.1%	1.59 [1.03, 2.43]	
Vinogradova 2011	273	10087	92	3534	23.3%	1.04 [0.82, 1.32]	
Total (95% CI)		**155932**		**64156**	**100.0%**	**1.20 [0.98, 1.45]**	
Total events	8814		3270				
Heterogeneity: Tau^2 = 0.03; Chi^2 = 11.03, df = 4 (P = 0.03); I^2 = 64%							
Test for overall effect: Z = 1.80 (P = 0.07)							

0.2 0.5 1 2 5
< 48 months ≥ 48 months

Figure 3. Forest plot of pancreatic cancer occurrence rate among patients who are taking statin less than 48 months and more than 48 months, respectively. The center of each square represents the weighted risk ratios for individual trials, and the corresponding horizontal line stands for a 95% confidence interval (CI). The diamonds represent pooled results.

It is worth highlighting here that the systematic reviews and meta-analyses conducted to date have focused mainly on determining the impact of long-term therapy on the prognosis of patients with diagnosed pancreatic cancer. One such meta--analysis showed a significantly better prognosis in patients diagnosed with pancreatic cancer (meta--hazard ratio [HR] = 0.75; 95% CI: 0.59–0.90; p < 0.001) compared to patients not receiving such treatment [50]. As in our meta-analysis, a significant limitation is the diversity of the population included in the review. A better prognosis of pancreatic cancer patients using statins has also been shown in another meta-analysis [51]. Similar observations were identified in another meta-analysis that included 14 studies. An interesting finding is a positive effect on outcomes in patients with the resectable disease, not seen in locally advanced or metastatic disease. This observation should encourage further research focused on reducing the risk of recurrence in patients undergoing treatment with the assumption of a radical cure [52]. The previously published systematic review of 2008 should be considered obsolete given new scientific evidence that has emerged since then [53]. In turn, the review that included studies describing the survival effects of both metformin and statins in patients diagnosed with pancreatic cancer was based on only 8 statin studies — although the article was published in 2018 [54]. These relationships, however, seem to be less potent than in the case of, for example, the influence of statins on progression of liver cirrhosis [55]. Newer data published recently from Norwegian registry pointed out, that statin users had lower mortality from pancreatic cancer (HR = 0.86, 95% CI: 0.76–0.97), and this association was more pronounced in users of hydrophilic (e.g., rosuvastatin) rather than lipophilic (e.g., atorvastatin) statins [56]. In a Japanese registry of 100,537 statin users vs. 326,033 non-statin users, after adjustments using inverse probability of treatment weighting, the statin exposure group was associated with a decreased incidence of pancreatic cancer (HR = 0.84; 95% CI: 0.72–0.99) [57]. It is striking, that this 14–16% relative reduction is almost identical in those 2 papers like in the present meta-analysis.

Further research should focus on the selection of populations in which statin use will be associated with a more significant reduction in the risk of developing pancreatic cancer compared to the general population. The starting point may be, in particular, the predictors that increase the risk of pancreatic cancer, especially the modifiable ones, e.g., a prospective observational study conducted among patients with nicotinism, the main modifiable risk factor for pancreatic cancer, next to obesity. Conducting a prospective clinical trial aimed at verifying the hypothesis that long-term statin use reduces the risk of developing pancreatic cancer would undoubtedly dispel doubts about the role of statins in the prevention of pancreatic cancer. Due to the long observation period necessary to demonstrate such a relationship, conducting a prospective clinical trial is highly difficult. It may turn out to be more convenient, as mentioned above, to design a clinical trial among a specified cohort of patients with a significantly increased risk of pancreatic cancer, e.g., in the family variant of this disease or specific genetic diseases.

Conclusions

The present analysis shows that overall statins use is significantly associated with a reduction in risk of pancreatic cancer. However, these results were not confirmed for the RCT sub-group. Further prospective studies are needed to confirm current results.

Conflict of interest: None declared

References

1. Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016; 22: 9694–9705, doi: 10.3748/wjg.v22.i44.9694, indexed in Pubmed: 27956793.
2. Ansari D, Tingstedt B, Andersson B, et al. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol. 2016; 12(16): 1929––1946, doi: 10.2217/fon-2016-0010, indexed in Pubmed: 27246628.
3. Torphy RJ, Fujiwara Y, Schulick RD. Pancreatic cancer treatment: better, but a long way to go. Surg Today. 2020; 50(10): 1117–1125, doi: 10.1007/s00595-020-02028-0, indexed in Pubmed: 32474642.
4. Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020; 69(1): 7–17, doi: 10.1136/gutjnl-2019-319352, indexed in Pubmed: 31672839.
5. McGuigan A, Kelly P, Turkington RC, et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018; 24(43): 4846–4861, doi: 10.3748/wjg.v24.i43.4846, indexed in Pubmed: 30487695.
6. Jiang MJ, Dai JJ, Gu DN, et al. Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials. Biochim Biophys Acta. 2016; 1866(2): 163–176, doi: 10.1016/j.bbcan.2016.08.002, indexed in Pubmed: 27567928.

7. Sun J, Li Y, Liu L, et al. Aspirin use and pancreatic cancer risk: A systematic review of observational studies. Medicine (Baltimore). 2019; 98(51): e18033, doi: 10.1097/MD.0000000000018033, indexed in Pubmed: 31860953.

8. Tan XL, Reid Lombardo KM, Bamlet WR, et al. Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study. Cancer Prev Res (Phila). 2011; 4(11): 1835–1841, doi: 10.1158/1940-6207. CAPR-11-0146, indexed in Pubmed: 21803981.

9. Li D, Ma Y, Liu W, et al. Celecoxib combined with salirasib strongly inhibits pancreatic cancer cells in 2D and 3D cultures. Int J Med Sci. 2020; 17(12): 1795–1802, doi: 10.7150/ijms.47546, indexed in Pubmed: 32714082.

10. Kho PF, Fawcett J, Fritschi L, et al. Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case-control study. Cancer Causes Control. 2016; 27(12): 1457–1464, doi: 10.1007/s10552-016-0824-4, indexed in Pubmed: 27817122.

11. Lai SW, Kuo YH, Liao KF. Statins and pancreatic cancer risk. J Gastroenterol. 2020; 55(4): 471–472, doi: 10.1007/s00535-020-01675-x, indexed in Pubmed: 32036452.

12. Carrer A, Trefely S, Zhao S, et al. Acetyl-CoA metabolism supports multistep pancreatic tumorigenesis. Cancer Discov. 2019; 9(3): 416–435, doi: 10.1158/2159-8290.CD-18-0567, indexed in Pubmed: 30626590.

13. Gong J, Sachdev E, Robbins LA, et al. Statins and pancreatic cancer. Oncol Lett. 2017; 13(3): 1035–1040, doi: 10.3892/ol.2017.5572, indexed in Pubmed: 28454210.

14. Lee HS, Lee SH, Lee HJ, et al. Statin use and its impact on survival in pancreatic cancer patients. Medicine (Baltimore). 2016; 95(19): e3607, doi: 10.1097/MD.0000000000003607, indexed in Pubmed: 27175667.

15. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021; 10(1): 89, doi: 10.1186/s13643-021-01626-4, indexed in Pubmed: 33781348.

16. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366: l4898, doi: 10.1136/bmj.l4898, indexed in Pubmed: 31462531.

17. Sterne JAc, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355: i4919, doi: 10.1136/bmj.i4919, indexed in Pubmed: 27733354.

18. McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021; 12(1): 55–61, doi: 10.1002/jrsm.1411, indexed in Pubmed: 32336025.

19. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414): 557–560, doi: 10.1136/bmj.327.7414.557, indexed in Pubmed: 12958120.

20. Archibugi L, Piciucchi M, Stigliano S, et al. Exclusive and combined use of statins and aspirin and the risk of pancreatic cancer: a case-control study. Sci Rep. 2017; 7(1): 13024, doi: 10.1038/s41598-017-13430-z, indexed in Pubmed: 29026148.

21. Bang UC, Watanabe T, Bendtsen F. The relationship between the use of statins and mortality, severity, and pancreatic cancer in Danish patients with chronic pancreatitis. Eur J Gastroenterol Hepatol. 2018; 30(3): 346–351, doi: 10.1097/MEG.0000000000001060, indexed in Pubmed: 29309396.

22. Bradley MC, Hughes CM, Cantwell MM, et al. Statins and pancreatic cancer risk: a nested case-control study. Cancer Causes Control. 2010; 21(12): 2093–2100, doi: 10.1007/s10552-010-9628-0, indexed in Pubmed: 20697797.

23. Carey FJ, Little MW, Pugh TFG, et al. The differential effects of statins on the risk of developing pancreatic cancer: a case-control study in two centres in the United Kingdom. Dig Dis Sci. 2013; 58(11): 3308–3312, doi: 10.1007/s10620-013-2778-7, indexed in Pubmed: 23864194.

24. Chen MJ, Tsan YT, Liou JM, et al. Statins and the risk of pancreatic cancer in Type 2 diabetic patients: a population-based cohort study. Int J Cancer. 2016; 138(3): 594–603, doi: 10.1002/ijc.29813, indexed in Pubmed: 26296262.

25. Chiu HF, Chang CC, Ho SC, et al. Statin use and the risk of pancreatic cancer: a population-based case-control study. Pancreas. 2011; 40(5): 669–672, doi: 10.1097/MPA.0b013e31821fd5cd, indexed in Pubmed: 21654539.

26. Clearfield M, Downs JR, Weis S, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Womens Health Gend Based Med. 2001; 10(10): 971–981, doi: 10.1089/152460901317193549, indexed in Pubmed: 11788107.

27. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology. 2007; 18(2): 213–219, doi: 10.1097/01.ede.0000254694.03027.a1, indexed in Pubmed: 17235211.

28. Graaf MR, Beiderbeck AB, Egberts ACG, et al. The risk of cancer in users of statins. J Clin Oncol. 2004; 22(12): 2388–2394, doi: 10.1200/JCO.2004.02.027, indexed in Pubmed: 15197200.

29. Haukka J, Sankila R, Klaukka T, et al. Incidence of cancer and statin usage--record linkage study. Int J Cancer. 2010; 126(1): 279–284, doi: 10.1002/ijc.24536, indexed in Pubmed: 19739258.

30. Jacobs EJ, Newton CC, Thun MJ, et al. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res. 2011; 71(5): 1763–1771, doi: 10.1158/0008-5472.CAN-10-2953, indexed in Pubmed: 21343395.

31. Kabat GC, Kim MY, Chlebowski RT, et al. Serum lipids and risk of obesity-related cancers in postmenopausal women. Cancer Causes Control. 2018; 29(1): 13–24, doi: 10.1007/s10552-017-0991-y, indexed in Pubmed: 29197994.

32. Karp I, Behlouli H, Lelorier J, et al. Statins and cancer risk. Am J Med. 2008; 121(4): 302–309, doi: 10.1016/j.amjmed.2007.12.011, indexed in Pubmed: 18374689.

33. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer. 2004; 90(3): 635–637, doi: 10.1038/sj.bjc.6601566, indexed in Pubmed: 14760377.

34. Khurana V, Sheth A, Caldito G, et al. Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas. 2007; 34(2): 260–265, doi: 10.1097/MPA.0b013e318030e963, indexed in Pubmed: 17312467.

35. Kirkegård J, Lund JL, Mortensen FV, et al. Statins and pancreatic cancer risk in patients with chronic pancreatitis: A Danish nationwide population-based cohort study. Int J Cancer. 2020; 146(3): 610–616, doi: 10.1002/ijc.32264, indexed in Pubmed: 30861115.

36. Leung HWC, Chan ALF, Lo D, et al. Common cancer risk and statins: a population-based case-control study in a Chinese population. Expert Opin Drug Saf. 2013; 12(1): 19–27, doi: 10.1517/14740338.2013.744392, indexed in Pubmed: 23199231.

37. Marelli C, Gunnarsson C, Ross S, et al. Statins and risk of cancer: a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. J Am Coll Cardiol. 2011; 58(5): 530–537, doi: 10.1016/j.jacc.2011.04.015, indexed in Pubmed: 21777752.

38. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med. 2008; 359(13): 1357–1366, doi: 10.1056/NEJMsa0806603, indexed in Pubmed: 18765432.

39. Sato S, Ajiki W, Kobayashi T, et al. PCS Study Group. Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study. J Epidemiol. 2006; 16(5): 201–206, doi: 10.2188/jea.16.201, indexed in Pubmed: 16951539.

40. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 287(24): 3215–3222, doi: 10.1001/jama.287.24.3215, indexed in Pubmed: 12076217.

41. Simon MS, Desai P, Wallace R, et al. Prospective analysis of association between statins and pancreatic cancer risk in the Women's Health Initiative. Cancer Causes Control. 2016; 27(3): 415–423, doi: 10.1007/s10552-016-0717-6, indexed in Pubmed: 26857832.

42. Strandberg T, Pyörälä K, Cook T, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). The Lancet. 2004; 364(9436): 771–777, doi: 10.1016/s0140-6736(04)16936-5, indexed in Pubmed: 15337403.

43. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer. 2011; 11: 409, doi: 10.1186/1471-2407-11-409, indexed in Pubmed: 21943022.

44. Walker EJ, Ko AH, Holly EA, et al. Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control study. Cancer. 2015; 121(8): 1287–1294, doi: 10.1002/cncr.29256, indexed in Pubmed: 25649483.

45. Zhang Y, Liang M, Sun C, et al. Statin use and risk of pancreatic cancer: an updated meta-analysis of 26 studies. Pancreas. 2019; 48(2): 142–150, doi: 10.1097/MPA.0000000000001226, indexed in Pubmed: 30640225.

46. Kawada T. Statin use and pancreatic cancer: A risk assessment. Dig Liver Dis. 2019; 51(5): 749, doi: 10.1016/j.dld.2019.02.011, indexed in Pubmed: 30926286.

47. Archibugi L, Arcidiacono PG, Capurso G. Statin use is associated to a reduced risk of pancreatic cancer: A meta-analysis. Dig Liver Dis. 2019; 51(1): 28–37, doi: 10.1016/j.dld.2018.09.007, indexed in Pubmed: 30314951.

48. Bonovas S, Filioussi K, Sitaras NM. Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies. Am J Gastroenterol. 2008; 103(10): 2646–2651, doi: 10.1111/j.1572-0241.2008.02051.x, indexed in Pubmed: 18684187.

49. Archibugi L, Arcidiacono PG, Capurso G. Statin use and pancreatic cancer: a risk assessment. Authors? reply. Dig Liver Dis. 2019; 51(5): 750–751, doi: 10.1016/j.dld.2019.02.021, indexed in Pubmed: 30926285.

50. Jian-Yu E, Graber J, Lu SE, et al. Effect of metformin and statin use on survival in pancreatic cancer patients: a systematic literature review and meta-analysis. Curr Med Chem. 2018; 25(22): 2595–2607, doi: 10.2174/0929867324666170412145232, indexed in Pubmed: 28403788.

51. Wang D, Rodriguez EA, Barkin JS, et al. Statin use shows increased overall survival in patients diagnosed with pancreatic cancer: a meta-analysis. Pancreas. 2019; 48(4): e22–e23, doi: 10.1097/MPA.0000000000001276, indexed in Pubmed: 30973465.

52. Tamburrino D, Crippa S, Partelli S, et al. Statin use improves survival in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Dig Liver Dis. 2020; 52(4): 392–399, doi: 10.1016/j.dld.2020.01.008, indexed in Pubmed: 32113888.

53. Bonovas S, Filioussi K, Sitaras N. Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies. Am J Gas-troenterol. 2008; 103(10): 2646–2651, doi: 10.1111/j.1572-0241.2008.02051.x, indexed in Pubmed: 28403788.

54. Jian-Yu E, Graber J, Lu SE, et al. Effect of metformin and statin use on survival in pancreatic cancer patients: a systematic literature review and meta-analysis. Curr Med Chem. 2018; 25(22): 2595–2607, doi: 10.2174/0929867324666170412145232, indexed in Pubmed: 28403788.

55. Gu Y, Yang X, Liang H, et al. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol. 2019; 19(1): 231, doi: 10.1186/s12876-019-1147-1, indexed in Pubmed: 31888534.

56. Støer NC, Bouche G, Pantziarka P, et al. Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway. Acta Oncol. 2021; 60(9): 1146–1153, doi: 10.1080/0284186X.2021.1953136, indexed in Pubmed: 34338111.

57. Saito K, Sato Y, Nakatani E, et al. Statin exposure and pancreatic cancer incidence: a Japanese regional population-based cohort study, the Shizuoka study. Cancer Prev Res (Phila). 2021; 14(9): 863–872, doi: 10.1158/1940-6207.CAPR-21-0123, indexed in Pubmed: 34244151.